{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:11:43Z","timestamp":1771546303373,"version":"3.50.1"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,3,1]]},"DOI":"10.1001\/jamaophthalmol.2023.6771","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:01:23Z","timestamp":1708012883000},"page":"271","source":"Crossref","is-referenced-by-count":5,"title":["Is Recommending 0.01% Atropine for Myopia Control Clinically Meaningful?"],"prefix":"10.1001","volume":"142","author":[{"given":"Safal","family":"Khanal","sequence":"first","affiliation":[{"name":"Department of Optometry and Vision Science, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Phillips","sequence":"additional","affiliation":[{"name":"School of Optometry and Vision Science, The University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"10","key":"ele230021r1","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial.","volume":"141","author":"Zadnik","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"ele230021r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.4206","article-title":"Clarifications for primary and secondary outcomes and analyses.","author":"Zadnik","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"ele230021r3","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1167\/iovs.02-0816","article-title":"A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children.","volume":"44","author":"Gwiazda","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"ele230021r4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-Dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial.","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"ele230021r5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jamaophthalmol.2022.0401","article-title":"Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial.","volume":"140","author":"Bao","year":"2022","journal-title":"JAMA Ophthalmol"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2814948\/jamaophthalmology_khanal_2024_le_230021_1710970264.26948.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T15:02:40Z","timestamp":1711033360000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2814948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.6771","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}